Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Profectus BioSciences Inc.

www.profectusbiosciences.com

Latest From Profectus BioSciences Inc.

Ebola Vaccines: FDA Being ‘More Liberal’ On Accelerated Approval, Novavax Says

Advisory committee likes alternative trial designs, but says more data is needed on immune markers.

BioPharmaceutical Regulation

Ebola Vaccines: FDA Weighs Alternative Study Designs, Approval Pathways

As incidence of Ebola declines, advisory committee will consider alternatives to randomized controlled trials – an approach FDA had previously argued was inappropriate.

BioPharmaceutical Middle East and Africa

Single dose of Profectus' Ebola vaccine works in monkeys

A single dose of Profectus BioSciences' experimental Ebola vaccine, which uses the firm's VesiculoVax vector platform, provided rapid and complete protection from sickness and death in macaques when challenged with a lethal dose of the Makona form of the Zaire virus – the strain responsible for the ongoing epidemic in West Africa, which has infected more than 25,500 people, killing over 10,500.

Immune Disorders Infectious Diseases

Profectus’ Ebola Vaccine To Enter Clinic In July, Trivalent Formulation Soon After

Profectus BioSciences announces positive results of its VesiculoVax-vectored Ebola vaccine in monkey study; at least four Ebola vaccines are in clinical testing as FDA prepares for May meeting.

BioPharmaceutical Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Profectus BioSciences Inc.
  • Senior Management
  • Jeffrey N Meshulam, COO
    John Eldridge, PhD, CSO
  • Contact Info
  • Profectus BioSciences Inc.
    Phone: (443) 743-1100
    6411 Beckley St.
    Baltimore, MD 21224
    USA
UsernamePublicRestriction

Register